Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein

被引：0
|
作者：
van Winkel, Claudia A.
Fan, Xiaoyu
Giesen, Danique
Gauderat, Glenn
Pattarini, Lucia
Jaquin, Thomas
Barakat, Anissa
De La Bigne, Anne-Marie
Richter, Marleen
Andersen, Nicole
Legrand, Julie
Lelievre, Helene
de Vries, Elisabeth G.
Morales-Kastresana, Aizea
Lub-de Hooge, Marjolijn N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3579
引用
收藏
页数：3
相关论文
共 50 条
  • [41] In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with 89Zr-labeled avelumab
    Li, Miao
    Ehlerding, Emily B.
    Jiang, Dawei
    Barnhart, Todd E.
    Chen, Weiyu
    Cao, Tianye
    Engle, Jonathan W.
    Cai, Weibo
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (05): : 1862 - 1872
  • [42] The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
    Peper-Gabriel, Janet K.
    Pavlidou, Marina
    Pattarini, Lucia
    Morales-Kastresana, Aizea
    Jaquin, Thomas J.
    Gallou, Catherine
    Hansbauer, Eva-Maria
    Richter, Marleen
    Lelievre, Helene
    Scholer-Dahirel, Alix
    Bossenmaier, Birgit
    Sancerne, Celine
    Riviere, Matthieu
    Grandclaudon, Maximilien
    Zettl, Markus
    Aiba, Rachida S. Bel
    Rothe, Christine
    Blanc, Veronique
    Olwill, Shane A.
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3387 - 3399
  • [43] ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT
    Jung, Uijung
    Jeon, Jaehyoung
    Lee, Shinai
    Jin, Hyung-Seung
    Kim, Youngkwang
    Sung, Eunsil
    Kim, Hyunjoo
    Lim, Yangmi
    Won, Jonghwa
    Wang, Zhengyi
    Jiang, Wenqing
    Jung, Jaeho
    You, Gihoon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A935 - A935
  • [44] DUOBODY®-PD-L1x4-1BB (GEN1046) INDUCES SUPERIOR IMMUNE-CELL ACTIVATION, CYTOKINE PRODUCTION AND CYTOTOXICITY BY COMBINING PD-L1 BLOCKADE WITH CONDITIONAL 4-1BB CO-STIMULATION
    Muik, Alexander
    Altintas, Isil
    Kosoff, Rachelle
    Gieseke, Friederike
    Schoedel, Kristina
    Salcedo, Theodora
    Burm, Saskia
    Toker, Aras
    Kranz, Lena
    Vormehr, Mathias
    Eisel, David
    Fereshteh, Mark
    Tuereci, Oezlem
    Breij, Esther
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A338 - A339
  • [45] Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Salcedo, Theodora
    Burm, Saskia
    Diken, Mustafa
    Grunwitz, Christian
    Schuurhuis, Danita
    Kreiter, Sebastian
    Satijn, David
    Tureci, Ozlem
    Breij, Esther
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [46] Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT
    Hegi-Johnson, F.
    Rudd, S.
    Callahan, J.
    Wichmann, C.
    Akhurst, T.
    Roselt, P.
    John, T.
    Donnelly, P.
    Scott, A.
    Hanna, G.
    MacManus, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S131 - S132
  • [47] QL301, a PD-L1 dependent 4-1BB agonist with enhanced preclinical anti-tumor efficacy and minimal liver toxicity
    Gu, Shenda
    Tang, Irene
    Mihardja, Shirley
    Prior, Wei Wei
    Tran, Hieu V.
    Chan, Allan
    McClain, Anna
    Kurtzman, Aaron
    Chen, Shihao
    Luo, Youguang
    Kang, Xiaoyan
    Wu, Xiaoran
    Zheng, Qingmei
    Jia, Guodong
    CANCER RESEARCH, 2022, 82 (12)
  • [48] ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma
    Mulgaonkar, Aditi
    Elias, Roy
    Woolford, Layton
    Guan, Bing
    Nham, Kien
    Kapur, Payal
    Christie, Alana
    Tcheuyap, Vanina T.
    Singla, Nirmish
    Bowman, I. Alex
    Stevens, Christina
    Hao, Guiyang
    Brugarolas, James
    Sun, Xiankai
    CLINICAL CANCER RESEARCH, 2022, 28 (22) : 4907 - 4916
  • [49] An Fc-inert PD-L1x4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schoedel, Kristina B.
    Burm, Saskia M.
    Toker, Aras
    Salcedo, Theodora W.
    Verzijl, Dennis
    Eisel, David
    Grunwitz, Christian
    Kranz, Lena M.
    Vormehr, Mathias
    Satijn, David P. E.
    Diken, Mustafa
    Kreiter, Sebastian
    Sasser, Kate
    Ahmadi, Tahamtan
    Tuereci, Oezlem
    Breij, Esther C. W.
    Jure-Kunkel, Maria
    Sahin, Ugur
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [50] TUMOR TARGETING AND TISSUE BIODISTRIBUTION OF RO7122290, A NOVEL FAP-TARGETED 4-1BB (CD137) AGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS, USING [89ZR]-RO7122290 AS A PET TRACER
    Garcia Velloso, Maria Jose
    Penuelas, Ivan
    Ponz-Sarvise, Mariano
    Sanmamed, Miguel
    Rodriguez-Ruiz, Maria
    Melero, Ignacio
    Vugts, Danielle
    Boellaard, Ronald
    Huisman, Marc
    van Dongen, Guus
    Guarin, Ernesto
    Heil, Florian
    Ceppi, Maurizio
    Canamero, Marta
    Matheisen, Camilla
    Iglesias, Francois
    Helbaj, Radoiane
    Krieter, Oliver
    Hettich, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A175 - A175
12345